Skip to main content
SGMO
NASDAQ Life Sciences

桑格莫治疗公司的现金储备仅够维持到第三季度，预示着未来可能面临稀释风险

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
7
Price
$0.278
Mkt Cap
$114.219M
52W Low
$0.299
52W High
$0.854
Market data snapshot near publication time

summarizeSummary

桑格莫治疗公司宣布，其当前的现金和现金等价物，加上最近一次发行的收益，预计只能维持其计划运营到第三季度。对于一家交易价格接近52周低点的小型生物技术公司来说，现金储备不足六个月是一个重大问题。这有限的流动性表明该公司需要通过进一步的稀释性股权发行来获得额外的资金，以维持第三季度后的运营。交易者将密切关注未来资本筹集公告和公司现金燃烧率的更新。

在该公告发布时，SGMO的交易价格为$0.28，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.1亿。 52周交易区间为$0.30至$0.85。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed SGMO - Latest Insights

SGMO
Apr 23, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
SVP Sells $89K in Shares Amidst Going Concern Warning and Delisting Threat
Sentiment: Negative
View Wiseek Article
SGMO
Mar 30, 2026, 5:31 PM EDT
Filing Type: 10-K
Importance Score:
10
Going Concern Warning, Imminent Delisting, and Highly Dilutive Financing Highlight Severe Financial Distress
Sentiment: Negative
View Wiseek Article
SGMO
Mar 30, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
10
Sangamo Therapeutics Issues Going Concern Warning, Citing Potential Bankruptcy Risk Amidst Significant Losses
Sentiment: Negative
View Wiseek Article
SGMO
Mar 30, 2026, 4:10 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Sangamo Therapeutics' Cash Runway Extends Only Into Q3, Signaling Future Dilution Risk
Sentiment: Negative
View Wiseek Article
SGMO
Mar 09, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
FDA Agrees to Accelerated Approval Endpoint for Sangamo's ST-920; Key BLA Modules Submitted
Sentiment: Positive
View Wiseek Article
SGMO
Feb 04, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
9
Sangamo Therapeutics Secures $25M in Highly Dilutive Offering and Reprices Existing Warrants
Sentiment: Negative
View Wiseek Article
SGMO
Feb 04, 2026, 8:31 AM EST
Filing Type: 424B5
Importance Score:
9
Sangamo Therapeutics Finalizes Highly Dilutive $24.8M Offering Amidst Going Concern Doubts
Sentiment: Negative
View Wiseek Article
SGMO
Feb 03, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
9
Sangamo Therapeutics Reports Positive Phase 1/2 STAAR Data for Fabry Gene Therapy, BLA Submission Underway
Sentiment: Positive
View Wiseek Article
SGMO
Feb 03, 2026, 9:07 AM EST
Filing Type: FWP
Importance Score:
9
Sangamo Therapeutics Details Highly Dilutive Offering, Warrant Repricing Amidst Going Concern and Delisting Risks
Sentiment: Negative
View Wiseek Article
SGMO
Feb 03, 2026, 8:55 AM EST
Filing Type: 8-K
Importance Score:
8
Sangamo Therapeutics Announces Principal Financial Officer Departure and Preliminary Low Cash Balance
Sentiment: Negative
View Wiseek Article